Reaction

Venoocclusive Disease reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,474 reports · 87 co-occurring drugs

As of the last recalculation, Venoocclusive Disease appears in 2,474 FAERS reports alongside 87 co-occurring drug terms. The strongest observed disproportionality signal is BUSULFAN (PRR 356.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Busulfan	525	356.1	368.4
Thiotepa	172	162.8	165.8
Fludarabine Phosphate	411	105.3	106.4
Melphalan Hydrochloride	259	97.0	98.0
Melphalan	217	87.9	88.7
Ursosiol	182	84.9	85.7
Ursodiol	185	77.2	77.8
Mesna Injection	61	63.7	64.1
Mesna	62	63.5	64.0
Blinatumomab	71	58.9	59.3
Anti-Thymocyte Globulin (Rabbit)	55	58.6	59.0
Heparin Sodium	85	53.8	54.1
Cytarabine	318	50.9	51.2
Alemtuzumab	104	47.2	47.4
Cyclophosphamide Injection, Solution	700	46.0	46.2
Cyclophosphamide	700	46.0	46.2
Cyclophosphamide For Injection	700	46.0	46.2
Acetylcysteine	47	42.8	43.0
Pegaspargase	56	39.3	39.5
Etoposide	286	36.9	37.0
Mercaptopurine	66	32.9	33.0
Vincristine Sulfate	100	29.9	30.0
Micafungin Sodium	26	26.1	26.1
Ifosfamide	63	25.3	25.4
Amphotericin B	35	23.8	23.9
Sirolimus	36	22.8	22.9
Cyclosporine	261	21.9	22.0
Brentuximab Vedotin	24	19.9	19.9
Bleomycin Sulfate	23	18.9	18.9
Ganciclovir Sodium	23	18.4	18.5
Ganciclovir	22	18.2	18.3
Filgrastim	74	17.0	17.1
Doxorubicin	157	15.8	15.8
Mycophenolate Mofetil Hydrochloride	231	15.7	15.7
Mycophenolate Mofetil	230	15.6	15.6
Granisetron Hydrochloride	18	14.6	14.6
Granisetron	18	14.5	14.6
Tacrolimus Ointment 0.1%	198	14.5	14.5
Tacrolimus Extended-Release Capsules	198	14.4	14.4
Methylprednisolone	208	13.7	13.7
Tacrolimus	220	12.9	12.9
Itraconazole	17	12.3	12.3
Fluconazole	95	11.8	11.8
Azacitidine For	25	11.7	11.7
Piperacillin Sodium,Tazobactam Sodium	35	11.2	11.3
Cefepime	18	10.6	10.6
Voriconazole	37	10.4	10.4
Cefepime Hydrochloride	19	10.0	10.0
Bendamustine Hydrochloride	14	9.9	9.9
Voriconazole Injection	25	9.8	9.8
Vancomycin	61	9.1	9.1
Phytonadione	9	9.0	9.0
Doxorubicin Hydrochloride	34	8.9	8.9
Methotrexate	380	8.8	8.8
Vancomycin Hydrochloride	67	8.8	8.8
Bendamustine Hcl	16	8.7	8.7
Azacitidine	30	8.6	8.6
Methotrexate Sodium	419	8.5	8.5
Meropenem	32	8.5	8.5
Hydroxyurea	21	8.4	8.4
Atovaquone	8	8.4	8.4
Imatinib	17	8.2	8.2
Phenytoin	20	8.1	8.1
Deferasirox	25	8.0	8.0
Posaconazole	15	7.8	7.8
Carboplatin	112	7.7	7.7
Posaconazole Delayed-Release	10	7.7	7.7
Acyclovir	96	7.3	7.3
Daspone	8	6.9	6.9
Dapsone Gel, 5%	8	6.9	6.9
Piperacillin Sodium And Tazobactam Sodium	16	6.9	6.9
Fosaprepitant Dimeglumine	11	6.8	6.8
Tranexamic Acid	7	6.6	6.6
Dapsone	8	6.3	6.3
Valganciclovir Hydrochloride Powder,	9	6.2	6.2
Alteplase	11	6.2	6.2
Mycophenilic Acid	15	6.1	6.1
Piperacillin And Tazobactam	9	5.9	5.9
Oxaliplatin	50	5.8	5.8
Aprepitant	12	5.5	5.5
Amikacin	10	4.9	5.0
Valacyclovir	24	4.9	4.9
Sorafenib	11	4.5	4.5
Dexamethasone 1.5 Mg	136	4.1	4.1
Cisplatin	33	3.6	3.6
Irinotecan Hydrochloride	5	3.3	3.3
Ruxolitinib	27	3.2	3.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.